Prothena to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that members of its senior management team will participate in a fireside chat at the H.C. Wainwright...